Alvaro Moreno-Aspitia, David W. Hillman, Stephen H. Dyar, Kathleen S. Tenner, Julie Gralow, Peter A. Kaufman, Nancy E. Davidson, Jacqueline M. Lafky, Monica M. Reinholz, Wilma L. Lingle, Leila A. Kutteh, Walter P. Carney, Amylou C. Dueck and Edith A. Perez Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831 Cancer 119
Version of Record online: 6 JUN 2013 | DOI: 10.1002/cncr.28130
There is great interest in finding biomarkers that can potentially prognosticate the risk of disease recurrence and predict the response to antihuman epidermal growth factor receptor 2 (HER2)-based therapies in early stage HER2-positive breast cancer. In the current study, the authors identify the soluble HER2 (sHER2) level as a prognostic marker associated with shorter disease-free survival and a high recurrence rate.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field